They further showed that pre-treatment of tumor-bearing mice with MTR prior to CAR T-cell infusion decreased plasma adrenaline and noradrenaline concentrations, reduced human CAR T-cell-derived IFN-γ and TNF-α, and reduced mouse-derived IL-6 and CXCL1 (44). This evidence concerns the gene CXCL1 and neoplasm.